MobileIron Research Reveals 8 in 10 IT Leaders Want to Eliminate Passwords and Expect Mobile Devices to Become Primary Authentication to the Enterprise
27.6.2019 15:00:00 EEST | Business Wire | Press release
MobileIron (NASDAQ:MOBL) today revealed the results of a survey conducted with IDG, which found that enterprise users and security professionals alike are frustrated by the inefficiency and lax security of passwords for user authentication. With 90% of security professionals reporting to have seen unauthorized access attempts as a result of stolen credentials, it’s clear that the future of security requires a next generation of authentication that’s more secure.
Mobile devices are the best option for replacing passwords, as they remain at the center of enterprises in terms of where business is done, how access is given, and how authentication is done. In fact, the survey revealed that almost nine-in-ten (88%) security leaders believe that mobile devices will soon serve as digital ID to access enterprise services and data.
The survey, sponsored by MobileIron, polled 200 IT security leaders in the US, UK, Australia, and New Zealand working in a range of industries at companies with at least 500 employees. The aim was to discover the major authentication pain points facing enterprises.
“It’s time to say goodbye to passwords. They not only cause major frustrations for users and IT professionals, but they also pose major security risks,” said Rhonda Shantz, Chief Marketing Officer at MobileIron. “That’s why MobileIron is ushering in a new era of user authentication with a mobile ID and zero sign-on experience from any device, any OS, any location, to any service. With more and more users accessing apps and company data via their own mobile devices, it’s not only easier to leverage mobile devices than passwords for user authentication – it’s also much more secure.”
The perils of passwords:
- 90% of security pros have seen unauthorized access attempts as a result of stolen credentials.
- Security leaders estimate that they could reduce their risk of breach by almost half by eliminating passwords.
- Two out of every five (41%) of helpdesk tickets result from password or multi-factor authentication (MFA) lockout,
- Password lockout sentiment for end-users: 68% feel disrupted; 63% feel irritated; 62% feel frustrated; 62% feel that they have wasted time.
- Almost half (45%) of all end-users reuse personal and corporate passwords, which does not comport with security best-practices.
- Security leaders estimate that they could reduce their risk of breach by almost half (43%) simply by eliminating passwords.
- Almost every security leader (86%) would do away with passwords if they could.
- Almost three-in-four (72%) security leaders are actively looking to replace passwords.
The merits of mobile:
- Almost nine-in-ten (88%) security leaders believe that in the near future, mobile devices will serve as your digital ID to access enterprise services and data.
-
About two-in-five end-users (42%) need daily access to mobile business apps, but that number is expected to grow significantly in the next two years.
- Almost all organizations saw the use of business apps expand last year (85%).
- Almost all organizations expect to see continued expansion in the next 2 years (87%).
- Millennials are driving demand for broader access to business apps on mobile devices (94% vs. 73% non-Millennials).
MobileIron recently introduced a revolutionary zero sign-on experience built on the company’s leading unified endpoint management (UEM) platform and powered by the MobileIron Access solution. MobileIron’s platform allows for continuous enforcement and protection of data, both on the device and on the network, with comprehensive correlation between the critical signals for zero trust: user, device, apps, networks, and threats. Zero sign-on completely eliminates passwords as the method for user authentication, replacing single sign-on, which still requires at least one username and password.
To download a complimentary copy of the IDG survey results, please visit here.
About MobileIron
MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190627005221/en/
Contact information
Becca Chambers
Head of Global Corporate Communications
bchambers@mobileiron.com
650.722.1647
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
